DEFA14A: Exact Sciences to be Acquired by Abbott in Q2 2026

Exact Sciences announced an agreement to be acquired by Abbott, a move expected to close in Q2 2026, aiming to expand patient reach and accelerate cancer diagnostics.

Summary

• Exact Sciences Corporation has entered into an agreement to be acquired by Abbott Laboratories.
• The acquisition is viewed as a significant milestone, celebrating the team's work and opening new opportunities.
• Joining Abbott will allow Exact Sciences to reach more patients faster, leveraging Abbott's scale and global resources to prevent cancer, detect it earlier, and guide treatment.
• Robert Ford, Abbott's CEO, visited Madison, highlighting the alignment of values and purpose between the two companies.
• Exact Sciences will operate as an independent company until the transaction closes, which is expected sometime in Q2 2026.
• Employees are instructed not to contact Abbott personnel directly unless part of the integration team, which will be formed shortly.
• Employees are encouraged to visit the Nucleus page for updates, read FAQs, notify managers or HR for questions, and join upcoming employee town halls.

Sentiment

Score: 8

Explanation: The sentiment is highly positive from management's perspective, expressing pride and excitement for the strategic benefits of the acquisition, despite the inclusion of standard forward-looking risks associated with such transactions.

Positives

• The acquisition by Abbott provides Exact Sciences with greater scale and global resources, enabling them to reach more patients faster.
• The transaction is expected to enhance Exact Sciences' mission to prevent cancer, detect it earlier, and guide personalized treatment.
• Management expressed deep pride in the company's achievements and excitement for future opportunities under Abbott.
• The visit from Abbott's CEO, Robert Ford, demonstrated a strong connection in values and purpose between the two organizations.

Risks

• Possible inability of the parties to consummate the proposed transaction on a timely basis or at all.
• Possible inability to satisfy conditions precedent to consummation, including necessary regulatory approvals and Exact Sciences stockholder vote.
• Potential occurrence of any event, change, or circumstance that could lead to the termination of the Merger Agreement.
• Risk that the Merger Agreement may be terminated, requiring Exact Sciences to pay a termination fee.
• Possibility that competing offers for Exact Sciences may be made.
• Potential adverse impact on Exact Sciences from contractual restrictions under the Merger Agreement that limit business opportunities or strategic transactions.
• Risks relating to significant transaction costs and the possibility that the transaction may be more expensive to complete than anticipated.
• Potential adverse effects of the announcement or pendency of the proposed transaction, or any failure to complete it, on Exact Sciences' stock price.
• Potential adverse effects on Exact Sciences' ability to develop and maintain relationships with personnel (including attracting and retaining management and scientific staff), customers, suppliers, and other business partners.
• Risks related to diversion of management's attention from ongoing business operations due due to the proposed transaction.
• Risk of litigation and/or regulatory actions related to the proposed transaction or Exact Sciences' business, and the outcome of any such actions.

Future Outlook

Exact Sciences expects to operate as an independent company until the acquisition by Abbott closes, which is anticipated in Q2. An integration team will be formed, and management plans to provide further updates after the Thanksgiving holiday, emphasizing continued focus on the company's mission and goals.

Management Comments

• "Yesterday was a meaningful and inspiring day for Exact Sciences. We announced our agreement to be acquired by Abbott, a milestone that celebrates the extraordinary work of this team and opens a new chapter filled with opportunity."
• "Joining Abbott allows us to reach more patients, faster. Their scale and global resources will help us prevent cancer, detect it earlier, and guide treatment for many more people."
• "It is critical that we stay focused on our mission and our goals."
• "I promise to keep sharing timely, honest updates as we confirm them."

Industry Context

This acquisition reflects a broader trend of consolidation within the healthcare and diagnostics industry, where larger players like Abbott seek to integrate specialized technologies and expand their market reach. By acquiring Exact Sciences, a leader in cancer diagnostics with products like Cologuard and Oncotype DX, Abbott aims to strengthen its position in the high-growth precision medicine and early detection segments, leveraging its global distribution and operational scale.

Corporate Governance

Legal Proceedings

• Risk of litigation and/or regulatory actions related to the proposed transaction or Exact Sciences' business, and the outcome of any such litigation or regulatory action.

Stakeholder Impact

• Shareholders: Will need to vote on the proposed transaction and will be impacted by the terms of the acquisition, including potential changes in stock value.
• Employees: Will experience an integration process, with instructions to remain focused on current missions and await guidance from an integration team. Potential for changes in roles, reporting structures, and corporate culture.
• Customers: The acquisition aims to expand reach and accelerate access to cancer prevention, detection, and treatment guidance, potentially leading to broader availability of Exact Sciences' tests.
• Suppliers: Relationships with suppliers may be impacted as Exact Sciences integrates into Abbott's larger supply chain and operational framework.

Next Steps

• Form an integration team for the acquisition.
• Employees are to visit the Nucleus page for the latest updates and materials.
• Employees are to read the FAQs for facts and guidance on questions.
• Employees should notify their manager or HR if they cannot find information.
• Employees are encouraged to join upcoming employee town halls and team sessions.
• Further updates will be shared after the Thanksgiving holiday.

Key Dates

Keywords

Exact Sciences, Abbott, acquisition, merger, cancer diagnostics, healthcare, biotechnology, Cologuard, Oncotype DX, SEC filing